Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma.

Joseph J NohYoung-Jae ChoJi-Yoon RyuJung-Joo ChoiJae Ryoung HwangJu-Yeon ChoiJeong-Won Lee

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The addition of cabozantinib to temozolomide offers synergistic anticancer effects in uterine sarcoma cell lines and xenograft mouse models, including PDX. These results warrant further investigation in a clinical trial.

Keyphrases

clinical trial
mouse model
metastatic renal cell carcinoma
newly diagnosed
phase ii
study protocol
cancer therapy
placebo controlled